National Institutes of Health

Resvita Bio develops and manufactures engineered probiotics for treating skin-related diseases, including cancer. Leveraging a synthetic biology platform, the company uses genetically engineered bacteria to produce and deliver therapeutic proteins directly to affected skin areas, providing continuous treatment and addressing limitations of traditional therapies. It targets conditions such as Netherton Syndrome and Severe Atopic Dermatitis, pursuing novel methods to manage skin disorders through localized, sustained protein delivery.

Nanopath is a molecular diagnostics company that develops innovative platforms for rapid disease diagnosis. Its technology enables point-of-care testing, eliminating the need for nucleic acid amplification and supporting multiplexed detection. This allows patients and healthcare providers to access accurate diagnostic results within standard office visits, improving healthcare outcomes.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Endomimetics develops bio-nanometric coating technology for stents, aiming to enhance care for patients with kidney disease. Its innovative coating mimics human tissue, reducing complications and surgeries associated with implanted devices.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery platforms and the development of quality-of-life medicines. The company focuses on enhancing drug discovery and manufacturing through its innovative biotechnology and nanotechnology solutions. Aphios offers a range of therapeutic products aimed at health maintenance, disease prevention, and the treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-based product, and various formulations of Taxotere for cancer treatment, which aim to improve oral bioavailability and target specific cancer cells. In addition to its therapeutic offerings, Aphios develops advanced technologies such as SuperFluids for pharmaceutical manufacturing and virology testing services, contributing to the safety and efficacy of drug therapies. Founded in 1993, Aphios continues to push the boundaries of medical science with its focus on innovative solutions for complex health challenges.

Chemeleon is a company that has developed an innovative platform technology for rapid and affordable diagnostics capable of detecting a wide array of analytes, including drugs, proteins, and viruses. Their proprietary in vitro diagnostic format delivers a colorimetric readout within minutes, visible to the naked eye, and does not require reagents, instruments, or specialized training. This decentralized testing approach empowers clinicians to extend point-of-care diagnostics and allows individuals to self-administer tests at the point of need. Chemeleon's diagnostics utilize highly selective molecular receptors combined with colorimetric nanomaterial reporters, facilitating immediate and actionable diagnoses that can significantly improve patient outcomes while reducing healthcare costs. Notably, the company developed a diagnostic for detecting beta-2-transferrin, a biomarker for Cerebrospinal Fluid leaks, resulting in substantial reductions in morbidity and healthcare expenses. With a focus on providing specificity and selectivity comparable to lab-based tests but in a fraction of the time and cost, Chemeleon's technology stands to transform healthcare accessibility, especially in resource-limited environments.

Matregenix is a MedTech company founded in 2018 by Sherif Soliman and based in Irvine, California. The company specializes in the development and manufacturing of advanced nanofibrous materials for various medical applications. Its flagship product, MatriNova, is a barrier membrane designed specifically for periodontal surgeries, featuring customizable properties such as predictable resorption time and ease of handling. Matregenix employs electrospinning technology to create innovative membrane solutions that cater to the filtration and biomedical sectors. In addition to its product offerings, the company provides comprehensive contract development and manufacturing services, assisting manufacturers in bringing their medical products to market effectively.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Partillion Bioscience is a life science company developing a platform for functional single-cell analysis. This platform enables rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, facilitating the development of advanced therapies for conditions like cancer, autoimmune disorders, and infectious diseases.

Nanoscope Therapeutics Inc. is a biotechnology company based in Bedford, Texas, focused on developing innovative gene therapies aimed at restoring vision for individuals affected by retinal degenerative diseases, such as retinitis pigmentosa and dry age-related macular degeneration. Established in 2017, the company specializes in light-sensitive molecules and employs light-assisted gene delivery techniques to enable targeted treatment that re-sensitizes the retina, allowing patients to perceive low light levels. By utilizing a unique optogenetic approach, Nanoscope Therapeutics aims to deliver a solution for vision loss in patients where no effective cure currently exists, thereby advancing the potential for vision restoration in millions of affected individuals.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Partillion Bioscience is a life science company developing a platform for functional single-cell analysis. This platform enables rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, facilitating the development of advanced therapies for conditions like cancer, autoimmune disorders, and infectious diseases.

Partillion Bioscience is a life science company developing a platform for functional single-cell analysis. This platform enables rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, facilitating the development of advanced therapies for conditions like cancer, autoimmune disorders, and infectious diseases.

Ceres Nanosciences specializes in the research, development, and commercialization of innovative sample preparation products based on its proprietary Nanotrap technology. This platform captures, enriches, and preserves biomarkers from various biofluid matrices, enabling early detection of diseases such as cancer, cardiac, and infectious diseases.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Ceres Nanosciences specializes in the research, development, and commercialization of innovative sample preparation products based on its proprietary Nanotrap technology. This platform captures, enriches, and preserves biomarkers from various biofluid matrices, enabling early detection of diseases such as cancer, cardiac, and infectious diseases.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Ceres Nanosciences specializes in the research, development, and commercialization of innovative sample preparation products based on its proprietary Nanotrap technology. This platform captures, enriches, and preserves biomarkers from various biofluid matrices, enabling early detection of diseases such as cancer, cardiac, and infectious diseases.

POP Biotechnologies, based in Buffalo, New York, is a life sciences company dedicated to enhancing patients' health through innovative nanomedicine solutions. The company focuses on developing targeted therapies for cancer and other serious diseases, utilizing its proprietary nanoparticle-based drug delivery systems activated by near-infrared light. This technology enables precise, controlled release of therapeutic payloads, aiming to improve patient outcomes in oncology and infectious disease treatment.

The Cornell High Energy Synchrotron Source is a science and technology laboratory. They assist in the development of equipment that supports research and experiments. They will make undulator beamtime available for certain user groups to create new tools, processes, and synchrotron radiation applications. They provide resources for physics, chemistry, biology, environmental science, and materials science research.

Chemeleon is a company that has developed an innovative platform technology for rapid and affordable diagnostics capable of detecting a wide array of analytes, including drugs, proteins, and viruses. Their proprietary in vitro diagnostic format delivers a colorimetric readout within minutes, visible to the naked eye, and does not require reagents, instruments, or specialized training. This decentralized testing approach empowers clinicians to extend point-of-care diagnostics and allows individuals to self-administer tests at the point of need. Chemeleon's diagnostics utilize highly selective molecular receptors combined with colorimetric nanomaterial reporters, facilitating immediate and actionable diagnoses that can significantly improve patient outcomes while reducing healthcare costs. Notably, the company developed a diagnostic for detecting beta-2-transferrin, a biomarker for Cerebrospinal Fluid leaks, resulting in substantial reductions in morbidity and healthcare expenses. With a focus on providing specificity and selectivity comparable to lab-based tests but in a fraction of the time and cost, Chemeleon's technology stands to transform healthcare accessibility, especially in resource-limited environments.

Neofluidics, established in 2014 and based in Carlsbad, California, specializes in developing and commercializing innovative microfluidics tools and technology. The company's flagship product, NeoPlate, is a well plate that significantly reduces testing costs by utilizing nanoliter sample volumes, catering to high throughput screening, point of care testing, and research and development applications. Additionally, Neofluidics offers NeoVisc, a smartphone-based microfluidic viscometer for real-time measurement of physical properties in various industries. The company serves clients in North America and internationally, with a portfolio of two proprietary patents and five product lines, including applications in the petroleum and military sectors. Since its launch in 2015, Neofluidics has fulfilled orders for numerous clients, demonstrating its commitment to enhancing workflow efficiency and reducing costs in the microfluidics industry.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

University of Nebraska Medical Center is the public center of health sciences research, patient care, and education in Omaha, Nebraska. It delivers education across medical and health fields, including nursing, pharmacy, physical therapy, physician assisting, and dental and medical training, with programs that train future doctors and dentists. The center conducts extensive research at its Durham Research Centers, pursuing advances in cancer treatments and transplant medicine. Small class sizes and close collaboration with faculty provide hands-on learning. It supports allied health programs such as clinical laboratory science, cytotechnology, medical sonography, and radiation therapy, and offers funding through research assistantships and fellowships. Beyond education and research, UNMC aims to improve patient care and contribute to the health of its state and communities through outreach and discovery.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.